Hypera S.A.
SAO: HYPE3.SA0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- B3 S.A.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Breno Toledo Pires de Oliveira
- Employees
- 10,481
- Headquarters
- São Paulo, Brazil
- IPO year
- 2008
- Market cap
- R$16.4B
- Website
- https://www.hyperapharma.com.br
Loading HYPE3…
Loading profile data…Frequently asked questions about HYPE3
What does Hypera S.A. (HYPE3.SA) do?
Hypera S.A. operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon,...
Where does HYPE3.SA trade?
Hypera S.A. (HYPE3.SA) trades on the B3 S.A..
What sector is HYPE3.SA in?
Hypera S.A. (HYPE3.SA) operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.
Who is the CEO of Hypera S.A.?
Breno Toledo Pires de Oliveira is the chief executive officer of Hypera S.A. (HYPE3.SA).
Where is Hypera S.A. headquartered?
Hypera S.A. is headquartered in Brazil.
Does HYPE3.SA pay a dividend?
Yes — Hypera S.A. (HYPE3.SA) paid a trailing twelve-month dividend of BRL 1.05 per share. Frequency and ex-dividend dates are tracked on the dividends tab.
When did HYPE3.SA go public?
Hypera S.A. (HYPE3.SA) completed its initial public offering in 2008.